https://www.selleckchem.com/pr....oducts/BMS-794833.ht
Emicizumab (Hemlibra Roche Switzerland) is a, humanized, bi-specific monoclonal modified immunoglobulin G4 (IgG4) which binds human FX, FIX and activated FIX (FIXa) to mimic activated FVIII activity. Evaluate the effects of emicizumab on the APTT, surrogate FVIII activity and FVIII inhibitor results. Two samples were provided, one obtained from an emicizumab treated severe haemophilia A patient with FVIII inhibitors and one constructed by in vitro addition of emicizumab using plasma from a severe haemophilia A patient without FVIII i
Like
Comment
Share
